ArticleFrontiers in pediatrics2025

A phase 1b randomized, multicenter, dose determination trial of zelpultide alfa (recombinant human surfactant protein D) in preterm neonates at high risk of developing bronchopulmonary dysplasia.

Almudena Alonso-Ojembarrena et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.